SARS-CoV-2 Testing in the Community: Testing Positive Samples with the TaqMan SARS-CoV-2 Mutation Panel To Find Variants in Real Time.
SARS-CoV-2 Testing in the Community: Testing Positive Samples with the TaqMan SARS-CoV-2 Mutation Panel To Find Variants in Real Time.
复制标题
社区中的SARS-CoV-2检测：使用TaqMan SARS-CoV-2突变小组检测阳性样本，以实时发现变异。
DOI：
10.1128/jcm.02408-21
复制
发表时间：
2022-04-20
影响因子：
9.4
通讯作者：
中科院分区：
文献类型：
--
作者：
基因组测序是识别 SARS-CoV-2 变异谱系的强大工具；然而，当用于识别特定的关键突变时，由于序列丢失，可能会存在局限性。最近，ThermoFisher Scientific 开发了基因分型测定，以帮助弥合测试能力和测序能力之间的差距，从而根据特定变异生成实时基因分型结果。在 2021 年 4 月和 5 月的 6 周时间内，我们着手评估 ThermoFisher TaqMan 突变面板基因分型测定，首先针对 SARS-CoV-2 阳性临床样本和相应的 COVID-19 Genomics UK Consortium (COG-UK) 测序数据评估三个关注突变，然后评估另外两个关注突变。我们证明，基因分型是一种用于识别特定突变的强大深入技术，是基因组测序的绝佳补充，并且具有真正的临床健康价值潜力，使实验室能够更快地报告关注的变异并采取行动。
Genome sequencing is a powerful tool for identifying SARS-CoV-2 variant lineages; however, there can be limitations due to sequence dropout when used to identify specific key mutations. Recently, ThermoFisher Scientific has developed genotyping assays to help bridge the gap between testing capacity and sequencing capability to generate real-time genotyping results based on specific variants. Over a 6-week period during the months of April and May 2021, we set out to assess the ThermoFisher TaqMan mutation panel genotyping assay, initially for three mutations of concern and then for an additional two mutations of concern, against SARS-CoV-2-positive clinical samples and the corresponding COVID-19 Genomics UK Consortium (COG-UK) sequencing data. We demonstrate that genotyping is a powerful in-depth technique for identifying specific mutations, is an excellent complement to genome sequencing, and has real clinical health value potential, allowing laboratories to report and take action on variants of concern much more quickly.
登录
查看更多内容
SARS-COV-2血统的估计可传播和影响B.1.1.7在英国。
DOI：
10.1126/science.abg3055
发表时间：
2021-04-09
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Davies NG;Abbott S;Barnard RC;Jarvis CI;Kucharski AJ;Munday JD;Pearson CAB;Russell TW;Tully DC;Washburne AD;Wenseleers T;Gimma A;Waites W;Wong KLM;van Zandvoort K;Silverman JD;CMMID COVID-19 Working Group;COVID-19 Genomics UK (COG-UK) Consortium;Diaz-Ordaz K;Keogh R;Eggo RM;Funk S;Jit M;Atkins KE;Edmunds WJ
通讯作者：
Edmunds WJ
影响因子：
12.3
作者：
Rang FJ;Kloosterman WP;de Ridder J
通讯作者：
de Ridder J
影响因子：
8.8
作者：
Meng B;Kemp SA;Papa G;Datir R;Ferreira IATM;Marelli S;Harvey WT;Lytras S;Mohamed A;Gallo G;Thakur N;Collier DA;Mlcochova P;COVID-19 Genomics UK (COG-UK) Consortium;Duncan LM;Carabelli AM;Kenyon JC;Lever AM;De Marco A;Saliba C;Culap K;Cameroni E;Matheson NJ;Piccoli L;Corti D;James LC;Robertson DL;Bailey D;Gupta RK
通讯作者：
Gupta RK
影响因子：
4.4
作者：
Vasudevan, Karthick;Ragupathi, Naveen Kumar Devanga;Veeraraghavan, Balaji
通讯作者：
Veeraraghavan, Balaji
影响因子：
6.4
作者：
Kidd, Michael;Richter, Alex;McNally, Alan
通讯作者：
McNally, Alan